Dr Reddys Laboratories
BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
Management Interviews on Dr Reddys Laboratories
Ranbaxy loses Valcyte exclusivity: An analysis
10.14 am | 07 Nov 2014 | Source: CNBC-TV18
Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche...
Quick Links for Dr Reddys Laboratories
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.